Motility, Parkinsonism, and prolactin with thiothixene and thioridazine

Arch Gen Psychiatry. 1981 Jun;38(6):668-75. doi: 10.1001/archpsyc.1981.01780310068007.


Clinical impressions suggest that thioridazine hydrochloride produces fewer extrapyramidal effects and more sedation than thiothixene. These drugs were given, each for three weeks, to 15 chronic schizophrenic outpatients in a counterbalanced, double-blind, crossover study. Spontaneous locomotion was recorded with an unobtrusive actometer toward the end of each three-week drug period. Surprisingly, patients were significantly more active with thioridazine, whereas parkinsonian scores, prolactin levels, and Brief Psychiatric Rating Scale scores remained about equal with the two drugs; thioridazine's extrapyramidal side effects were not "atypical." There are some explanations for why common clinical impressions and recent rodent studies have not predicted these results.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Motor Activity / drug effects*
  • Parkinson Disease, Secondary / chemically induced*
  • Prolactin / blood*
  • Schizophrenia / blood
  • Schizophrenia / drug therapy*
  • Thioridazine / adverse effects
  • Thioridazine / therapeutic use*
  • Thiothixene / adverse effects
  • Thiothixene / therapeutic use*


  • Thiothixene
  • Prolactin
  • Thioridazine